NEW YORK, Feb. 17, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Mauna Kea Technologies (Euronext Paris: MKEA; OTCQX: MKEAY), a global medical device company headquartered in Paris, France, has qualified to have its American Depositary Receipts (ADRs) trade on the OTCQX® Best Market.
Mauna Kea begins trading today on OTCQX under the symbol "MKEAY," where each ADR represents two ordinary shares. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We're pleased to welcome Mauna Kea to our family of established, investor-focused OTCQX companies," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Trading on the OTCQX market will allow Mauna Kea to expand its shareholder base and visibility in the North American markets while providing U.S. investors a convenient method to trade its securities and access the company's news and financial disclosure. We look forward to helping Mauna Kea grow and prosper."
"Continuing to build on a strong presence in North America is strategically important to Mauna Kea. With 10 separate FDA clearances and 140 U.S. Cellvizio installations today, including the majority of leading U.S. academic medical centers and a global commercial partnership in urology with a leading American medical device firm, Cook Medical, we have solid foundations in the American market. Later this year, we will relocate our U.S. operations to Boston, a recognized nexus for medical innovation. Finally, in joining the OTCQX market, we are pleased to achieve a milestone that places the Company in close proximity to many of the world's most sophisticated healthcare investors," said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies.
BNY Mellon serves as Mauna Kea's Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements.
Mauna Kea is a global medical device company focused on protecting patients' lives while enabling physicians and surgeons to make better decisions thanks to direct visualization at the cellular level. The company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into markets to inform investors of opportunities and risks: the OTCQX® Best Market; the OTCQB® Venture Market; and the Pink® Open Market. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial markets, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, email@example.com
SOURCE OTC Markets Group Inc.